Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 86
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/19/2006
1.
Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Renal Cell Carcinoma --- A Modified Group C Study (Summary Last Modified 04/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
16 and over
NCI-C87-0001
AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001
Last Modified:
10/19/2006
2.
Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Malignant Melanoma --- A Modified Group C Study (Summary Last Modified 04/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
16 and over
NCI-C87-0002
AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002
Last Modified:
1/1/1988
3.
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Carcinoma of the Colon (Summary Last Modified 01/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 to 70
UCCRC-4973A
NCI-V87-0310
Last Modified:
1/1/1988
4.
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Malignant Melanoma (Summary Last Modified 01/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 to 70
UCCRC-4973B
NCI-V87-0311
Last Modified:
4/26/2007
5.
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 01/88)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 to 70
UCCRC-4973C
NCI-V87-0312
Last Modified:
11/1/1990
6.
Phase II/III Adoptive Immunotherapy for Metastatic Renal Cell Carcinoma: Systemic IL-2 plus IL-2-Activated/Periodate-Treated Cells (Summary Last Modified 11/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
21 to 70
NYH-1088-350CRC
NCI-V88-0417
Last Modified:
4/1/1991
7.
Phase III Prospectively Randomized Study of Adoptive Immunotherapy with High-Dose Recombinant IL-2 Administered Alone vs High-Dose Recombinant IL-2 Administered in Conjunction with Systemic Administration of LAK Cells in Patients with Advanced Cancer (Summary Last Modified 04/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
any age
NCI
NCI-86-C-46
NCI-T86-0097N, T86-0097
Last Modified:
10/1/1989
8.
Phase III Prospectively Randomized Study of Surgery Alone vs Surgery plus Adjuvant Immunotherapy with High-Dose Recombinant IL-2 vs Surgery plus Adjuvant High-Dose Recombinant IL-2 in Conjunction with the Systemic Administration of LAK Cells in Patients with Stage II Melanoma (Summary Last Modified 10/89)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
any age
NCI
NCI-86-C-50
NCI-T86-0099N, T86-0099
9.
Phase III Prospective Randomized Study of Adjuvant Immunotherapy with High-Dose Recombinant IL-2/LAK Cells in Patients with Locally Advanced Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
NCI-86-C-157A
NCI-T86-0247N, T86-0247
Last Modified:
12/1/1990
10.
Phase III Randomized Study of Infusional IL-2 Alone vs with Adoptive Immunotherapy Using IL-2-Pulsed Mononuclear Peripheral Blood Cells in Patients with Advanced Renal Cancer (Summary Last Modified 12/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NBSG-9007
NCI-V90-0143
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute